Effects of antiviral therapy on the cellular immune response in acute hepatitis C
Fareed Rahman,Theo Heller,Yuji Sobao,Eishiro Mizukoshi,Michelina Nascimbeni,Harvey J. Alter,Steven K. Herrine,Jay H. Hoofnagle,T. Jake Liang,Barbara Rehermann +9 more
Reads0
Chats0
TLDR
A sustained response to antiviral therapy was not associated with a lasting enhancement of HCV‐specific T‐cell responsiveness in the blood, as previously reported.About:
This article is published in Hepatology.The article was published on 2004-07-01 and is currently open access. It has received 141 citations till now. The article focuses on the topics: Hepatitis C virus & Ribavirin.read more
Citations
More filters
Journal ArticleDOI
Mechanism of action of interferon and ribavirin in treatment of hepatitis C
Jordan J. Feld,Jay H. Hoofnagle +1 more
TL;DR: A better understanding of the mechanism of action of IFN and ribavirin will be essential to optimize current therapeutic strategies and to develop new therapies.
Journal ArticleDOI
Hepatitis C virus versus innate and adaptive immune responses: a tale of coevolution and coexistence
TL;DR: The clinical, virological, and immunological features of acute and chronic hepatitis C and the role of the immune response in spontaneous and treatment-induced HCV clearance are discussed.
Journal ArticleDOI
Hepatitis C Virus Continuously Escapes From Neutralizing Antibody and T-Cell Responses During Chronic Infection In Vivo
Thomas von Hahn,Joo Chun Yoon,Harvey J. Alter,Charles M. Rice,Barbara Rehermann,Peter Balfe,Peter Balfe,Jane A. McKeating,Jane A. McKeating +8 more
TL;DR: During chronic infection HCV is subjected to selection pressures from both humoral and cellular immunity, resulting in the continuous generation of escape variants.
Journal ArticleDOI
Flying Under the Radar: The Immunobiology of Hepatitis C
Lynn B. Dustin,Charles M. Rice +1 more
TL;DR: It is proposed that HCV takes advantage of the impaired innate response to delay the organization of an effective adaptive immune attack, and the tolerogenic liver environment may provide cover, prolonging this delay.
Journal ArticleDOI
Dysfunction and functional restoration of HCV-specific CD8 responses in chronic hepatitis C virus infection.
Amalia Penna,Massimo Pilli,Alessandro Zerbini,Alessandra Orlandini,Sergio Mezzadri,Luca Sacchelli,Gabriele Missale,Carlo Ferrari +7 more
TL;DR: This study characterizes CD8 defects that may be important in maintaining HCV persistence; identification of strategies to correct these defects may help to define novel approaches to treat HCV infection.
References
More filters
Journal ArticleDOI
Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection.
Michael W. Fried,Mitchell L. Shiffman,K. Rajender Reddy,C. Smith,George Marinos,Fernando L. Gonçales,Dieter Häussinger,Moisés Diago,Giampiero Carosi,Daniel Dhumeaux,Antonio Craxì,A. Lin,Joseph Hoffman,Jian Yu +13 more
TL;DR: In patients with chronic hepatitis C, once-weekly peginterferon alfa-2a plus ribavirin was tolerated as well as interferonAlfa- 2b plus Ribavirin and produced significant improvements in the rate of sustained virologic response, as compared with interfer on alfa -2b plus ribvirin or pegin terferonalfa-3a alone.
Journal ArticleDOI
Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial.
Michael P. Manns,John G. McHutchison,Stuart C. Gordon,Vinod K. Rustgi,Mitchell L. Shiffman,Robert Reindollar,Zachary Goodman,Kenneth Koury,Mei Hsiu Ling,Janice K. Albrecht +9 more
TL;DR: In patients with chronic hepatitis C, the most effective therapy is the combination of peginterferon alfa-2b 1.5 microg/kg per week plus ribavirin, and this randomised trial found that the benefit is mostly achieved in patients with HCV genotype 1 infections.
Journal ArticleDOI
Effector and memory T-cell differentiation: implications for vaccine development
TL;DR: The signals required for commitment to this programme of development and the factors that might influence its progression are discussed and models of the pathways of effector and memory T-cell differentiation are discussed.
Journal ArticleDOI
Natural history of chronic hepatitis C
TL;DR: Efforts to determine natural history are handicapped by the primary characteristics of the disease, namely that its onset rarely is recognized and its course is prolonged exceedingly, so that at least 20% of chronically infected adults develop cirrhosis within 20 years.
Journal ArticleDOI
Analysis of Successful Immune Responses in Persons Infected with Hepatitis C Virus
Franziska Lechner,David Wong,P R Dunbar,Roger W. Chapman,Raymond T. Chung,P B Dohrenwend,Gregory K. Robbins,Rodney E. Phillips,Paul Klenerman,Bruce D. Walker +9 more
TL;DR: A strong and persistent CTL response in resolving acute HCV infection is demonstrated, and rationale to explore immune augmentation as a therapeutic intervention in chronic HCv infection is provided.